Merck and Moderna diverge on cancer vaccine results. Do they still have a viable drug?

Moderna and Merck stock diverged Friday as investors digested the early release of their cancer vaccine data.

Moderna and Merck stock diverged Friday as investors digested the early release of their cancer vaccine data.

Source: MSN The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.